DDInter1016 DDInter1000
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023.
Ivosidenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Ivosidenib {u} may lead to a major life threatening interaction when taken with {v} Alfuzosin
Ivosidenib {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Ivosidenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Ivosidenib may lead to a major life threatening interaction when taken with Alfuzosin
Ivosidenib may lead to a major life threatening interaction when taken with Oliceridine